Drug intelligence / Profile preview

mirtazapine + olanzapine

Development stage: Preclinical
Lead developer: Teva Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

A combination of the antidepressant mirtazapine and the antipsychotic olanzapine. Mirtazapine is a tetracyclic antidepressant that works by antagonizing adrenergic alpha-2 autoreceptors and heteroreceptors, as well as blocking serotonin 5-HT2 and 5-HT3 receptors. Olanzapine is an atypical antipsychotic that primarily blocks dopamine D2 receptors and serotonin 5-HT2A receptors. This combination is used for treating complex psychiatric conditions including depression with psychotic features, anorexia nervosa with comorbid depression, and treatment-resistant depression.

Targets

HTR3A (5-hydroxytryptamine receptor 3A)ADRA2A (α2A)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on mirtazapine + olanzapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mirtazapine + olanzapine.

Explore the full profile